http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017149333-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e27e42f54229c326eb8692b524d4974 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2017-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bc9e8b1a5eece9ad939858d9e0104c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_147ff558ebd4829354639ebbceb2b142 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58fc684388fbfc8cdf527b60b54613f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159de7d3bc45fd57cc7a7d4958cd404d |
| publicationDate | 2017-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2017149333-A1 |
| titleOfInvention | Novel types of c-3 substituted kinurenic acid derivatives with improved neuroprotective activity |
| abstract | The invention relates to C-3 substituted kynurenic acid derivatives with the general formula (I) wherein R 1 is C 1-7 alkyl-, R 6 R 7 N-C 1-7 alkyl-, C 6-10 aryl-C 1-7 alkyl group; R 2 is H or C 1-7 alkyl group; or R 1 and R 2 with the nitrogen atom to which they are attached form a saturated or partially saturated 5-7 membered, optionally benzofused heterocyclic ring, optionally comprising additional N, O, S heteroatoms and optionally being substituted; R 3 is -OH, C 1-7 alkyl-O-, -NH 2 , C 1-7 alkyl-NH-, C 6-10 aryl-C 1-7 alkyl-NH- or -NH- -(CH 2 ) n -NR 8 R 9 group wherein n is an integer from 1 to 3; R 4 is H, C 1-7 alkyl-, C 6-10 aryl group or a halogen atom; R 5 is H or C 6-10 aryl group; R 6 is C 1-7 alkyl group; R 7 is C 1-7 alkyl group; or R 6 and R 7 with the nitrogen atom to which they are attached form a saturated or partially saturated 5-7 membered, optionally benzofused heterocyclic ring, optionally comprising additional N, O, S heteroatoms and optionally being substituted; R 8 is C 1-7 alkyl group; R 9 is C 1-7 alkyl group; R 8 and R 9 with the nitrogen atom to which they are attached form a saturated or partially saturated 5-7 membered, optionally benzofused heterocyclic ring, optionally comprising additional N, O, S heteroatoms and optionally being substituted; and stereoisomers, tautomers and salts thereof. The invention relates to the pharmaceutical preparations comprising the compounds and stereoisomers, tautomers and pharmaceutically acceptable salts. The compounds of the invention have neuroprotective activity, may be used for the prevention and treatment of neurodegeneration, and for slowing down the development of the conditions and diseases associated with a decline in cognitive abilities. |
| priorityDate | 2016-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 172.